Lisata Therapeutics Inc is a publicly traded company operating in the Biotechnology industry. Its shares trade on NASDAQ NMS - GLOBAL MARKET under the ticker LSTA, with a market capitalization of approximately $30 million. A full business summary isn’t available for this company yet — the figures and signals on this pa…
An institutional-grade, numbers-driven thesis on LSTA — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates Lisata Therapeutics Inc (LSTA) 50/100 with a 12-month base-case forecast of $3.29 — -1.2% versus the current price of $3.33. Lisata Therapeutics Inc trades at $3.33 in the Biotechnology sector, with a market capitalisation of $30.3M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for LSTA is $3.29, implying -1.2% versus the current price. The model's 12-month scenario range runs from $2.88 (bear) to $3.83 (bull), with a base case of $3.29.
On the fundamentals, Lisata Therapeutics shows trailing revenue of $175823, revenue growth of -27.1% YoY. This page also tracks LSTA's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
LSTA currently carries a TradersQuant composite score of 50/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "buy". Our 12-month price target of $3.29 implies -1.2% from $3.33. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for LSTA is $3.29, about -1.2% versus the latest price of $3.33. Consensus is based on 9 analysts.
TradersQuant's 12-month model forecast for LSTA is a base case of $3.29, ranging from $2.88 (bear) to $3.83 (bull), an expected return of -1.3%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for LSTA over the next 12 months is $3.29 in the base case (bear $2.88, bull $3.83), versus today's price of $3.33. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for LSTA — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates LSTA's fair value at $4.16, implying +25.0% of expected upside versus the current price.
Lisata Therapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
